Matthew Cunningham, MD
Ophthalmology · Orlando, FLNPI 1336303247
Payments from drug & device makers
Across 1,126 payments — averaging $2598.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$976K
- Genentech, Inc.$571K
- Regeneron$485K
- Ocular Therapeutix, Inc.$152K
- Novartis$127K
- ANI Pharmaceuticals, Inc.$125K
- plus $490K from 22 others
Across 24 payments — averaging $1386.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$16K
- F. Hoffmann-la Roche AG$16K
- Genentech, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 319 | $975,901 |
| Genentech, Inc. | 41 | $571,173 |
| Regeneron | 271 | $484,990 |
| Ocular Therapeutix, Inc. | 8 | $152,457 |
| Novartis | 31 | $126,519 |
| ANI Pharmaceuticals, Inc. | 16 | $124,932 |
| Genentech USA, Inc. | 85 | $93,803 |
| Apellis Pharmaceuticals, Inc. | 51 | $82,817 |
| Astellas Pharma US Inc | 53 | $78,049 |
| Regeneron Healthcare Solutions, Inc. | 72 | $66,321 |
| Boehringer Ingelheim | 6 | $49,680 |
| Boehringer Ingelheim Finland Ky | 30 | $29,553 |
| Alcon | 43 | $28,684 |
| AbbVie(2 entities) | 41 | $27,239 |
| Eyepoint US, Inc. | 6 | $14,680 |
| Alimera Sciences, Inc. | 28 | $10,127 |
| Alcon Research LLC | 3 | $4,660 |
| US Retina LLC | 11 | $2,792 |
| Boehringer Ingelheim International GmbH | 1 | $1,250 |
| Mallinckrodt Hospital Products Inc. | 2 | $117 |
| Harrow Eye, LLC | 1 | $116 |
| Beaver-visitec International, Inc. | 1 | $107 |
| Dutch Ophthalmic, USA | 1 | $92 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Bausch & Lomb Americas Inc. | 1 | $32 |
| Neurotech Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,926,218 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Orlando
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Benjamin ThomasJacksonville$2.8M
- Priya VakhariaPalm Harbor$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.